Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 192-200

  Vaidyanathan, Sujata ^a   Warren, Vance ^a   Yeh, Chingming ^a   Bizot, Marie Noelle ^b   Dieterich, Hans Armin ^a   Dole, William P ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Aliskiren; Liver; Pharmacokinetics; Reninangiotensin system

Indexed keywords

ALISKIREN; RENIN INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER DYSFUNCTION; MACULOPAPULAR RASH; MALE; MUSCLE CRAMP; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE;

AMIDES; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; LIVER DISEASES; RENIN;

EID: 33846456943     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006294404     Document Type: Article

References (34)

1. Kearney, PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 ; 365: 217-223.
2. Antikainen RL, Moltchanov VA, Chukwuma C Sr, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 13-29.
3. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens. 2003 ; 21: 1599-1608.
4. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens Suppl. 2005 ; 23: S9 - S17.
5. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990 ; 15: 276-282.
6. Azizi M, Menard J. Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004 ; 109: 2492-2499.
7. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957 ; 106: 439-453.
8. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005 ; 16: 592-599.
9. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 ; 308: 698-705.
10. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 ; 39: E1 - E8.
11. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 ; 111: 1012-1018.
12. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003 ; 42: 1137-1143.
13. Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens Suppl. In press.
14. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 1996 ; 24: 461-473.
15. Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol. In press.
16. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999 ; 37: 399-431.
17. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005 ; 43: 527-535.
18. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol. 2004 ; 58: 433-436.
19. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther. 2006 ; 79-79: 64 ( PIII-24 ).
20. Valencia J, Vaidyanathan S, Kemp C, et al. Lack of pharmaco-kinetic interactions of the direct oral renin inhibitor aliskiren with amlodipine, ramipril, valsartan and hydrochlorthiazide. J Clin Pharmacol. In press.
21. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists: an update. Clin Pharmacokinet. 1992 ; 22: 416-433.
22. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens. 1997 ; 11 (suppl 2). S37 - S42.
23. Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol. 1998 ; 38: 347-356.
24. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005 ; 44: 797-814.
25. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997 ; 62: 272-278.
26. Tenero D, Martin D, Chapelsky M et al. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy. 1998 ; 18: 42-50.
27. von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl. 2001 ; 19: S33 - S40.
28. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol. 2000 ; 40: 1355-1364.
29. Vaidyanathan S, Limoges D, Yeh C, Dieterich H. Aliskiren, an orally effective renin inhibitor, shows dose-linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2006 ; 79-79: 64 ( PIII-23 ).
30. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers. Clin Pharmacol Ther. 2006 ; 79-79: 2 ( PI-20 ).
31. Mitchell J, Oh B, Herron J, Chung J, Khan M, Satlin A. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens. 2006 ; 8 (5 suppl A). P-209 - P-209.
32. Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit. 2001 ; 6: 9-16.
33. Vaidyanathan S, Jermany J, Yeh C, Bizot M, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. In press.
34. Weir MR, Bush C, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J (Suppl). In press.